$LSTA News

Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts Approximately 72% Of Full-Time Employees

Lisata Therapeutics Terminates Merger Agreement With Kuva Labs; Termination Due To Kuva Labs' Failure To Obtain Financing, Accept Tendered Shares; Board To Carry Out Strategic Options Including Asset Sale

Lisata Therapeutics Stock Falls After Hours: Here's Why

Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share

Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.

Kuva Acquisition Commences Tender Offer To Purchase All Issued And Outstanding Shares Of Common Stock Of Lisata Therapeutics For $4.00/Shr In Cash At Closing, Plus One Non-Tradeable Contingent Value Right

HC Wainwright & Co. Downgrades Lisata Therapeutics to Neutral

Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances

Lisata Therapeutics shares are trading higher after the company entered into a definitive agreement to be acquired by Kuva Labs.

Lisata Therapeutics shares are trading higher after the company entered into a definitive agreement to be acquired by Kuva Labs.

Reported Friday, Lisata Therapeutics To Be Taken Private By Kuva Labs In A Deal Offering Stockholders $5.00 Per Share Plus A $1.00 Contingent Value Right Per Share

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

What Does the Market Think About Lisata Therapeutics Inc?

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Lisata Therapeutics shares are trading higher after the company announced that it has mutually terminated the February 2021 Exclusive License and Collaboration Agreement with Qilu Pharmaceutical.

Lisata Therapeutics, Qilu Pharmaceutical Mutually Terminate 2021 License And Collaboration Agreement

How The Evolving Story For Lisata Therapeutics (LSTA) Is Reshaping Its Valuation Outlook

Brookline Capital Downgrades Lisata Therapeutics to Hold

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Why Is Lisata Therapeutics Stock Gaining Today?